Promomed's revenue for 9 months of 2025 amounted to ₽19 billion, an increase of 78% compared to last year. Revenue growth is 6 times higher than the growth rate of the pharmaceutical market, which amounted to 12.6%. Share of revenue from the sale of drugs in the endocrinological and oncological portfolios increased by 22 percentage points and amounted to 75%. In the endocrinology segment, revenue increased 2.6 times, to ₽8 billion. In the oncology segment, revenue increased 2.3 times and reached 5.9 billion rubles.